Article | March 23, 2022

Reducing Protocol Deviations With Training-Based Metrics

Source: Pro-ficiency
Training skills learning GettyImages-1353769234

Protocol deviations can have a detrimental effect on new drug development, adding to costs and time to clinical trials and even putting the acceptability of data generated during a study at risk. Despite this, protocol deviations seem to be viewed as just part of doing business in the clinical research arena. And one question that arises is whether training in individual protocols is adequate, given the frequency with which deviations occur.

In its recent analysis of inspectional findings during 2021, the FDA said in its annual BIMO metrics report that protocol deviations or failure to follow the investigational plan was the most common observation listed on Form 483s after a BIMO inspection. This was also the most-frequent Form 483 observation during 2020, and has been at the top of the list for the last several years, the FDA noted.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader